# name
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery

# metadata.dc.description.abstract[].value
The adaptation of existing antimalarial nanocarriers to new
                Plasmodium stages, drugs, targeting molecules, or encapsulating
                structures is a strategy that can provide new
                nanotechnology-based, cost-efficient therapies against malaria.
                We have explored the modification of different liposome
                prototypes that had been developed in our group for the targeted
                delivery of antimalarial drugs to Plasmodium-infected red blood
                cells (pRBCs). These new models include: (i)
                immunoliposome-mediated release of new lipid-based
                antimalarials; (ii) liposomes targeted to pRBCs with covalently
                linked heparin to reduce anticoagulation risks; (iii) adaptation
                of heparin to pRBC targeting of chitosan nanoparticles; (iv) use
                of heparin for the targeting of Plasmodium stages in the
                mosquito vector; and (v) use of the non-anticoagulant
                glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate
                for pRBC targeting. The results presented indicate that the
                tuning of existing nanovessels to new malaria-related targets is
                a valid low-cost alternative to the de novo development of
                targeted nanosystems.

# metadata.dc.relation.ispartof[].value
Nanomedicine: Nanotechnology, Biology and Medicine, 2017, vol. 13, num. 2, p. 515-525

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery